{"id":1006502,"date":"2026-09-29T07:45:31","date_gmt":"2026-09-29T11:45:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\/"},"modified":"2026-09-29T07:45:31","modified_gmt":"2026-09-29T11:45:31","slug":"neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\/","title":{"rendered":"NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CARMEL, Ind., Sept.  29, 2026  (GLOBE NEWSWIRE) &#8212; NeurAxis, Inc. (\u201cNeurAxis\u201d or the \u201cCompany\u201d) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced the appointment of Craig Blanchard as Chief Commercial Officer. In this role, Mr. Blanchard will oversee the Company\u2019s commercial functions, including sales and marketing.<\/p>\n<p align=\"justify\">The appointment of Mr. Blanchard as Chief Commercial Officer represents a strategic investment in the significant growth opportunity NeurAxis sees ahead. With the Company expecting to expand its commercial organization alongside a substantial increase in covered lives, NeurAxis is strengthening its leadership and sales infrastructure to support broader adoption of IB-Stim and capitalize on its expanding market opportunity.<\/p>\n<p align=\"justify\">\u201cCraig joins NeurAxis at an important inflection point in our commercial growth,\u201d said Brian Carrico, President and Chief Executive Officer of NeurAxis. \u201cAs we prepare to significantly expand our commercial organization and anticipate a substantial increase in covered lives, his experience building sales teams, launching innovative medical technologies and driving market adoption will be invaluable. We believe Craig\u2019s leadership will help us translate expanding reimbursement coverage into broader physician adoption and increased patient access to IB-Stim.\u201d<\/p>\n<p align=\"justify\">Mr. Blanchard brings NeurAxis extensive experience in commercialization, market development, and healthcare technology adoption. Previously, he served as Vice President of Product Strategy, Marketing and Field Clinical at NICO Corporation, where he led commercial strategy for minimally invasive neurosurgery technologies and helped drive multiple products from launch through market adoption, with NICO technologies impacting more than 40,000 patients and leading to its acquisition by Stryker in 2024.<\/p>\n<p align=\"justify\">Earlier in his career, Mr. Blanchard held commercial leadership roles at Boston Scientific and Guidant Corporation, with responsibilities spanning sales growth, national accounts, and product commercialization.<\/p>\n<p align=\"justify\">NeurAxis\u2019 proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia, and FD associated nausea symptoms, in patients 8 years and older. IB-Stim is a non-invasive neuromodulation device that gently stimulates cranial nerve bundles in the ear to help regulate pain signaling between the gut and the brain. Currently, no FDA-approved drug therapies exist for pediatric patients with abdominal pain-related disorders of gut-brain interaction (DGBIs), a significant unmet medical need. In the absence of approved options, off-label prescription drugs are often used, despite limited efficacy data and potential safety concerns\u2014underscoring IB-Stim\u2019s unique position as the only FDA-cleared therapy specifically designed for this large and underserved pain related patient population.<\/p>\n<p align=\"justify\">\n        <strong>About NeurAxis, Inc.<br \/><\/strong>NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of IB-Stim, its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA-cleared for functional abdominal pain in irritable bowel syndrome (IBS) and functional dyspepsia, including FD-linked nausea symptoms in patients ages 8 and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FEqfi3m0kJQ5eTdv7VXfstZCeha06vQf1wL5UGCsKVM9lwxX-GdXw7wVKDmXTuaR7eDMnNNlYs-Do8dTzqLIXnBAk8Fw9RCrfQZHFJCZ94g=\" rel=\"nofollow\" target=\"_blank\">http:\/\/neuraxis.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Company<\/strong><br \/>\n        <br \/>\n        <strong>NeurAxis, Inc.<\/strong><br \/>\n        <br \/>info@neuraxis.com<br \/>For contraindications, precautions, warnings, and IFU, please see: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HoqR69BENU8UsX7JhNuKIeCdQAbFw6Clg76ou6nrUm_BbBbehQuPfdcQe6Y3OSYFHhJV2iPiIYa4G0HkBh16x8aGwxDbBd_d0JhaE5jl8rmBbPNzbUroK4eXkCwrLLO4GCmFwscW5jooJ84jmKVXRA==\" rel=\"nofollow\" target=\"_blank\">https:\/\/ibstim.com\/important-information\/<\/a>.<\/p>\n<p>\n        <strong>Investor Relations<\/strong><br \/>\n        <br \/>Lytham Partners<br \/>Ben Shamsian<br \/>646-829-9701<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6hFtSfea3nZWTbq0BqwAJgf0OM7BTF3ta4OT9tKumMmaekz4038VavQUE--PecZ8vG5B2vl-C24RXxFfNiPRmk4g3vYh17pzSvRQk9zTgeJLBRYQLpa3lihvH14hUyyR\" rel=\"nofollow\" target=\"_blank\">shamsian@lythampartners.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTE4OSM3ODU3NjUwIzIyNTIyNDI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDNkMWZiZDUtMzVhMC00Mzk2LWI0YzctODkzNDJkOTNkYzBkLTEyNjM3OTUtMjAyNi0wOS0yOS1lbg==\/tiny\/NeurAxis-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) &#8212; NeurAxis, Inc. (\u201cNeurAxis\u201d or the \u201cCompany\u201d) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced the appointment of Craig Blanchard as Chief Commercial Officer. In this role, Mr. Blanchard will oversee the Company\u2019s commercial functions, including sales and marketing. The appointment of Mr. Blanchard as Chief Commercial Officer represents a strategic investment in the significant growth opportunity NeurAxis sees ahead. With the Company expecting to expand its commercial organization alongside a substantial increase in covered lives, NeurAxis is strengthening its leadership and sales infrastructure to support broader adoption of IB-Stim and capitalize on its expanding market opportunity. \u201cCraig joins NeurAxis &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1006502","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) &#8212; NeurAxis, Inc. (\u201cNeurAxis\u201d or the \u201cCompany\u201d) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced the appointment of Craig Blanchard as Chief Commercial Officer. In this role, Mr. Blanchard will oversee the Company\u2019s commercial functions, including sales and marketing. The appointment of Mr. Blanchard as Chief Commercial Officer represents a strategic investment in the significant growth opportunity NeurAxis sees ahead. With the Company expecting to expand its commercial organization alongside a substantial increase in covered lives, NeurAxis is strengthening its leadership and sales infrastructure to support broader adoption of IB-Stim and capitalize on its expanding market opportunity. \u201cCraig joins NeurAxis &hellip; Continue reading &quot;NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-29T11:45:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTE4OSM3ODU3NjUwIzIyNTIyNDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer\",\"datePublished\":\"2026-09-29T11:45:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\\\/\"},\"wordCount\":557,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNTE4OSM3ODU3NjUwIzIyNTIyNDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\\\/\",\"name\":\"NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNTE4OSM3ODU3NjUwIzIyNTIyNDI=\",\"datePublished\":\"2026-09-29T11:45:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNTE4OSM3ODU3NjUwIzIyNTIyNDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNTE4OSM3ODU3NjUwIzIyNTIyNDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\/","og_locale":"en_US","og_type":"article","og_title":"NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer - Market Newsdesk","og_description":"CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) &#8212; NeurAxis, Inc. (\u201cNeurAxis\u201d or the \u201cCompany\u201d) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced the appointment of Craig Blanchard as Chief Commercial Officer. In this role, Mr. Blanchard will oversee the Company\u2019s commercial functions, including sales and marketing. The appointment of Mr. Blanchard as Chief Commercial Officer represents a strategic investment in the significant growth opportunity NeurAxis sees ahead. With the Company expecting to expand its commercial organization alongside a substantial increase in covered lives, NeurAxis is strengthening its leadership and sales infrastructure to support broader adoption of IB-Stim and capitalize on its expanding market opportunity. \u201cCraig joins NeurAxis &hellip; Continue reading \"NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-29T11:45:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTE4OSM3ODU3NjUwIzIyNTIyNDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer","datePublished":"2026-09-29T11:45:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\/"},"wordCount":557,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTE4OSM3ODU3NjUwIzIyNTIyNDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\/","name":"NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTE4OSM3ODU3NjUwIzIyNTIyNDI=","datePublished":"2026-09-29T11:45:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTE4OSM3ODU3NjUwIzIyNTIyNDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTE4OSM3ODU3NjUwIzIyNTIyNDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuraxis-positions-for-next-phase-of-commercial-growth-with-appointment-of-craig-blanchard-as-chief-commercial-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006502","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1006502"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006502\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1006502"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1006502"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1006502"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}